NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,813.60+₹52.60 (+2.99%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.48% below the high.
Loading market information…
NSE · HESTERBIO.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:44 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Hester Biosciences Limited’s quoted price sits in the upper half of its reported 52-week range, 13.75% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Hester Biosciences Limited’s forward annual dividend is ₹11.00 per share, paid annual. The forward yield is 0.48% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Hester Biosciences Limited’s next earnings report is currently expected on Nov 5, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Hester Biosciences Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Hester Biosciences Limited, founded in 1987 and headquartered in Ahmedabad, India, specializes in the production and commercialization of veterinary vaccines and a comprehensive array of animal health solutions. The company's operations span both domestic and international markets, structured around two primary divisions: Poultry Healthcare and Animal Healthcare. Its extensive range of poultry vaccines targets numerous conditions, including Newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, egg drop syndrome, reovirus infections, Marek's disease, infectious coryza, fowl cholera, mycoplasma gallisepticum, inclusion body hepatitis, and avian encephalomyelitis. For larger animals, Hester Biosciences provides vaccines designed to combat ailments such as Goat Pox, Peste des Petits Ruminants (PPR), Brucellosis, Mastitis, Metritis, various infectious diseases, reproductive disorders, theileriosis, and parasitic infestations. Beyond vaccines, the company's product portfolio encompasses vital feed supplements like toxin binders, trace minerals, enzyme preparations, and bypass fats. It also supplies disinfectants for maintaining farm hygiene and sanitizing equipment, along with water purification solutions. Nutritional support products are offered, including mineral mixtures, fertility boosters, and growth tonics. A significant portion of their offerings consists of herbal preparations, featuring growth promoters, natural alternatives to choline chloride, stress and immunity enhancers, respiratory aids, liver tonics, wound healing agents, uterine and digestive tonics, anti-bloat remedies, ectoparasiticides, and treatments for anti-mastitis and anti-prolapse conditions.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,813.60+₹52.60 (+2.99%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.48% below the high.
₹9,807.00+₹143.00 (+1.48%)
Divi's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 0.35% below the high.
₹4,636.70+₹56.70 (+1.24%)
Torrent Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 11.68% below the high.
₹661.00-₹19.90 (-2.92%)
Bliss GVS Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 10.66% below the high.
₹19.58-₹0.83 (-4.07%)
Syncom Formulations (India) Limited’s quoted price sits in the upper half of its reported 52-week range, 28.77% below the high.
₹213.40-₹8.54 (-3.85%)
Jagsonpal Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 19.32% below the high.
₹307.00-₹5.85 (-1.87%)
Bajaj Healthcare Ltd’s quoted price sits in the lower half of its reported 52-week range, 37.21% below the high.
₹26.59-₹0.01 (-0.04%)
Sigachi Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 34.83% below the high.
